PCR Journal Club

The objective of this study was to validate standardised clinical criteria for BVD and evaluate its association with mortality and rehospitalisation, thereby guiding optimal valve selection in clinical practice.

The AD-HOC Registry aimed to evaluate procedural success and clinical outcomes of current-generation BEVs and SEVs in treating stenotic Sievers type 1 BAV.

The TCW trial found that FFR-guided PCI with TAVI offers favorable one-year outcomes, including lower rates of all-cause mortality, MI, disabling stroke, revascularisation, valve reintervention, and severe bleeding, compared to CABG with SAVR.

This study aims to evaluate changes in microcirculatory function post-TAVI, specifically assessing resting and hyperaemic absolute coronary flow and microvascular resistance before TAVI, immediately post, and at 6-month follow-up.

The present study explores the alternative of 1 suture-based + 1 plug closure device vs. the conventional one, finding a superiority of this approach in achieving the full closure, hemostasis with a reduced incidence of complications. 

In this analysis, the 3-year outcomes of the TRILUMINATE study are presented, evaluating the long-term effectiveness of the TriClip T-TEER system on TR reduction, right ventricular remodeling, quality of life, and heart failure symptoms.

The review aims to address the unmet needs in heart failure (HF) management, particularly in patients where structural heart disease coexists with HF and limits the effectiveness of guideline-directed medical therapy (GDMT).

The take-home message for clinicians is that in the treatment of tricuspid regurgitation, the most frequent valvular disease alongside aortic stenosis, redefining procedural success as a function of the residual degree of TR is crucial.

This study highlights the TRISCORE's role in assessing risk for patients undergoing TTVI. Despite limitations, TRISCORE effectively identifies high-risk patients, aiding decision-making in a complex landscape of valvular heart disease management.

This trial sought to compare the procedural and clinical outcomes of ACURATE neo/neo2 and EVOLUT R/PRO/Pro+ valves for ViV procedures.